Literature DB >> 16709028

Characteristics of tumor-associated endothelial cells derived from glioblastoma multiforme.

Christiana Charalambous1, Thomas C Chen, Florence M Hofman.   

Abstract

Glioblastomas multiforme (GBMs) are highly vascular brain tumors characterized by abnormal vessel structures in vivo. This finding supports the theory that glioma-associated endothelial cells (ECs) have intrinsically different properties from ECs in normal human brain. Therefore, identification of the functional and phenotypic characteristics of tumor-associated ECs is essential for designing a rational antiangiogenic therapy. The GBM-associated ECs have a large, flat, and veil-like appearance, in contrast to normal ones, which are small and plump. Although the tumor ECs have the typical markers, they proliferate more slowly than these cell types in normal brain. The GBM-associated ECs are resistant to cytotoxic drugs, and they undergo less apoptosis than control cells. Also, GBM-associated ECs migrate faster than controls and constitutively produce high levels of growth factors such as endothelin-1, interleukin-8, and vascular endothelial growth factor. An understanding of these unique characteristics of glioma-associated ECs is important for the development of novel antiangiogenic agents that specifically target tumor-associated ECs in gliomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16709028     DOI: 10.3171/foc.2006.20.4.e22

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  21 in total

Review 1.  Chemokines as mediators of angiogenesis.

Authors:  Borna Mehrad; Michael P Keane; Robert M Strieter
Journal:  Thromb Haemost       Date:  2007-05       Impact factor: 5.249

2.  Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche.

Authors:  David W Infanger; YouJin Cho; Brina S Lopez; Sunish Mohanan; S Chris Liu; Demirkan Gursel; John A Boockvar; Claudia Fischbach
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

Review 3.  Chemokines as mediators of tumor angiogenesis and neovascularization.

Authors:  Ellen C Keeley; Borna Mehrad; Robert M Strieter
Journal:  Exp Cell Res       Date:  2010-10-30       Impact factor: 3.905

4.  A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis.

Authors:  Dezheng Dong; Christopher Stapleton; Biquan Luo; Shigang Xiong; Wei Ye; Yi Zhang; Niyati Jhaveri; Genyuan Zhu; Risheng Ye; Zhi Liu; Kevin W Bruhn; Noah Craft; Susan Groshen; Florence M Hofman; Amy S Lee
Journal:  Cancer Res       Date:  2011-04-05       Impact factor: 12.701

5.  Loss of endothelial programmed cell death 10 activates glioblastoma cells and promotes tumor growth.

Authors:  Yuan Zhu; Kai Zhao; Anja Prinz; Kathy Keyvani; Nicole Lambertz; Ilonka Kreitschmann-Andermahr; Ting Lei; Ulrich Sure
Journal:  Neuro Oncol       Date:  2015-08-08       Impact factor: 12.300

Review 6.  Pharmacotherapy for adults with tumors of the central nervous system.

Authors:  Nina F Schor
Journal:  Pharmacol Ther       Date:  2008-11-27       Impact factor: 12.310

Review 7.  Adhering towards tumorigenicity: altered adhesion mechanisms in glioblastoma cancer stem cells.

Authors:  Soumya M Turaga; Justin D Lathia
Journal:  CNS Oncol       Date:  2016-09-12

Review 8.  Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma.

Authors:  R E Kast
Journal:  J Neurooncol       Date:  2009-03-26       Impact factor: 4.130

9.  Vascular gene expression patterns are conserved in primary and metastatic brain tumors.

Authors:  Yang Liu; Eleanor B Carson-Walter; Anna Cooper; Bethany N Winans; Mahlon D Johnson; Kevin A Walter
Journal:  J Neurooncol       Date:  2010-01-09       Impact factor: 4.130

Review 10.  Chemokines as mediators of neovascularization.

Authors:  Ellen C Keeley; Borna Mehrad; Robert M Strieter
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-08-28       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.